LLY On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
EN Paris
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000


5 not including possible patent extension); Portrazza is protected by a compound patent (2025 not including possible patent extension), and by biologics data package protection (2027); Strattera is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016) plus pediatric exclusivity (2017); Trajenta and Jentadueto are protected by a compound patent (2023), and Boehringer Ingelheim has applied for a patent extension to 2025 under the patent restoration laws; and Trulicity is protected by a compound patent (2024 not including possible patent extension) and by biologics data package protection (2026). Outside the U.S., primary patent protection or data protection comprises Alimta in major European countries (compound patent 2015, vitamin regimen patent 2021) and Japan (compound patent December 2015, patent covering use to treat cancer concomitantly with vitamins 2021); Cialis in major European countries (compound patent 2017); Cymbalta in Japan (data package protection 2018); Forteo in Japan (data package protection 2018; patent covering its formulation and related process 2019); and Zyprexa in Japan (patent for bipolar mania would expire April 2016). Patent Licenses The compound patent for Cialis is the subject of a license agreement with GlaxoSmithKline (Glaxo), which assigns to the company all rights in the compound. The compound patent for Alimta is the subject of a license agreement with Princeton University, granting the company an irrevocable exclusive worldwide license to the compound patents for the lives of the patents in the respective territories. Alimta is also the subject of a worldwide, nonexclusive license to certain patents owned by Takeda Pharmaceutical Company Limited. Government Regulation Pursuant to the Federal Food, Drug, and Cosmetic Act, the U.S. Food and Drug Administration has jurisdiction over all of the company’s human pharmaceutical products and certain animal health products in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, advertising, dissemination of information, and post-marketing surveillance of those products. Outside the U.S., the company’s products and operations are subject to similar regulatory requirements, including by the European Medicines Agency in the EU and the Ministry of Health, Labor and Welfare in Japan. History Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The company was incorporated in 1901 in Indiana.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LLY.
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 33.9x
Price/Sales 4.0x
Price/Book 5.7x
Price/Cash Flow 35.2x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.